K2 Medical Research, LLC

The trials here

What the 14 trials at this site are about, from their registry records.

Conditions

• Alzheimer disease12 trials
• Mild cognitive impairment3 trials
• Parkinson disease2 trials
• Frontotemporal dementia1 trial

Phase

• Phase 36 trials
• Phase 14 trials
• Phase 22 trials
• Phase 1/21 trial

Status

• Active, not recruiting5 trials
• Recruiting5 trials
• Completed2 trials
• Enrolling by invitation1 trial
• Terminated1 trial

Lead sponsor

• Hoffmann-La Roche4 trials
• Alzheon Inc.2 trials
• Eli Lilly and Company2 trials
• Cognition Therapeutics1 trial
• Eisai Inc.1 trial
• and 4 more

Running trials

• Recruiting

  A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

  NCT07717411· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease

  NCT07764146· Phase 1· Voyager Therapeutics· Source

  Contact: Recruitment Coordinator

• Recruiting

  SAD Study in Patients With Parkinson's Disease and Motor Fluctuations

  NCT07422675· Phase 1· Serina Therapeutics· Source

  Contact: Sheila Baez-Torres, MD (principal investigator)

• Active, not recruiting

  A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

  NCT07169578· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease

  NCT07094516· Phase 2· Novartis Pharmaceuticals· Source

• Recruiting

  Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

  NCT07177352· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease

  NCT06297590· Phase 1· Eli Lilly and Company· Source

  Contact: Brandon Lenox (principal investigator)

• Enrolling by invitation

  Alzheimer's Plasma Extension

  NCT06416072· University of Southern California· Source

• Active, not recruiting

  A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease

  NCT05531656· Phase 2· Cognition Therapeutics· Source

• Active, not recruiting

  Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease

  NCT04639050· Phase 1/2· Hoffmann-La Roche· Source

• Active, not recruiting

  AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

  NCT04468659· Phase 3· Eisai Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Alzheimer disease5 recruiting
• Mild cognitive impairment2 recruiting
• Frontotemporal dementia1 recruiting
• Parkinson disease1 recruiting

Closed trials

• Recruiting

  A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease

  NCT06809400· Phase 1· Eli Lilly and Company· Source

• Terminated

  Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

  NCT06304883· Phase 3· Alzheon Inc.· Source

• Completed

  An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects

  NCT04770220· Phase 3· Alzheon Inc.· Source